Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
Konstantinos Liapis & Ioannis Kotsianidis, on behalf of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes.
We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website. You can decide for yourself which categories you want to deny or allow. Please note that based on your settings not all functionalities of the site are available.
Further information can be found in our privacy policy.